Key facts
- DermaScan’s last known valuation is $950K (Dec 2024).
- It has raised $2.8M; the latest was Early Stage VC ($2.5M) in Feb 2026.
- Notable investors include Kima Ventures, Techmind, Ring Capital, Celine Lazorthes, 199 Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for DermaScan
- ·The full record, as it builds
Funding rounds
No funding rounds for DermaScan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DermaScan
Provider of skin cancer screening services designed to detect and manage skin cancer risk. The facility offers body mapping, analysis of suspicious lesions, diagnosis, and follow-up plans, with referrals to dermatologists as needed, consultations utilizing advanced technology for skin cancer detection, enabling patients to diagnose skin cancer at an early stage.
- Sector
- Healthcare
- HQ
- Paris, France
- Employees
- 9
- Website
- dermascan.fr/
- Ownership
- Privately Held (backing)
DermaScan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DermaScan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DermaScan in its N-PORT filings yet. We sweep new filings monthly.